Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aiml Resources ( (TSE:AIML) ) has issued an announcement.
AI/ML Innovations’ subsidiary Neural Cloud Solutions has signed a distribution agreement with Chile-based digital health provider Intelimed.ai to commercialize its MaxYield, CardioYield and Insight 360 cardiac software platforms across Latin America. Intelimed is granted exclusive distribution rights in Chile and non-exclusive rights in the wider region, targeting hospitals, clinics, diagnostic providers, OEMs, telemedicine firms and research institutions.
The deal positions Chile as a strategic anchor market and taps Intelimed’s existing network and “platform” model for clinical AI, aiming to accelerate adoption of Neural Cloud’s ECG enhancement and automated reporting tools. With Latin America seeking scalable, cost-effective diagnostic technologies, the partnership is intended to expand access to advanced cardiac AI solutions that fit local clinical workflows while adhering to international standards, potentially strengthening AIML’s regional foothold in digital health.
The most recent analyst rating on (TSE:AIML) stock is a Sell with a C$0.04 price target. To see the full list of analyst forecasts on Aiml Resources stock, see the TSE:AIML Stock Forecast page.
Spark’s Take on TSE:AIML Stock
According to Spark, TipRanks’ AI Analyst, TSE:AIML is a Neutral.
The score is primarily held down by persistent heavy losses and ongoing cash burn despite strong TTM revenue growth, which increases dependence on external funding. Technicals are mixed-to-weak with the stock below longer-term moving averages and a negative MACD, while valuation is constrained by a negative P/E and no dividend yield data.
To see Spark’s full report on TSE:AIML stock, click here.
More about Aiml Resources
AI/ML Innovations Inc. is a global technology company focused on transforming digital health through artificial intelligence and neural networks. Its proprietary platforms apply advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights, supporting earlier diagnosis, personalized treatment and more effective care across healthcare settings.
Average Trading Volume: 390,632
Technical Sentiment Signal: Sell
Current Market Cap: C$10.16M
For an in-depth examination of AIML stock, go to TipRanks’ Overview page.